Stockscreener 앱 받기
0.3528
0.77%
0.0027
시간 외 거래:
.36
0.0072
+2.04%
전일 마감가:
$0.3501
열려 있는:
$0.355
하루 거래량:
1.13M
Relative Volume:
0.29
시가총액:
$56.34M
수익:
$506.20K
순이익/손실:
$-42.05M
주가수익비율:
-1.3328
EPS:
-0.2647
순현금흐름:
$-31.36M
1주 성능:
-12.24%
1개월 성능:
+41.12%
6개월 성능:
+7.96%
1년 성능:
-81.91%
1일 변동 폭
$0.3457
$0.3667
1주일 범위
$0.3457
$0.403
52주 변동 폭
$0.20
$2.37
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
명칭
Mereo Biopharma Group Plc Adr
전화
4403330237300
주소
ONE CAVENDISH PLACE, LONDON
Compare MREO vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
0.3528 | 59.09M | 506.20K | -42.05M | -31.36M | -0.2647 |
VRTX
Vertex Pharmaceuticals Inc
|
505.64 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
196.48 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
742.12 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
928.44 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
200.87 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-12-30 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-03-27 | 개시 | JP Morgan | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-06-13 | 개시 | Robert W. Baird | Outperform |
| 2023-10-13 | 재개 | BTIG Research | Buy |
| 2022-08-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-05 | 개시 | BTIG Research | Buy |
| 2021-04-05 | 개시 | Needham | Buy |
모두보기
Mereo Biopharma Group Plc Adr 주식(MREO)의 최신 뉴스
Mereo BioPharma Group PLC ADR (NASDAQ: MREO) Stock Price, News & Analysis - Kalkine
Mereo BioPharma Group plcADR Peer Comparison – Compare with Others - Value Research
Mereo BioPharma | MREO USAnnouncementsPresentations - Smartkarma
Form 8K MEREO BIOPHARMA GROUP PLC For: 19 August By Investing.com - Investing.com Nigeria
Mereo BioPharma (NASDAQ: MREO) given 2027 Nasdaq deadline - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Here's Why We're Not Too Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Situation - Sahm
Mereo BioPharma Q2 Results: Net loss narrows 52% YoY to $7.0 million - scanx.trade
Form 8K MEREO BIOPHARMA GROUP PLC For: 11 August By Investing.com - Investing.com South Africa
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights - GlobeNewswire
Defilade Capital Management L.P. Makes New Investment in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPhar - The National Law Review
MAH0 Forecast — Price Target — Prediction for 2027 - TradingView
MREO News | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) - ChartMill
MREO - Finviz
Mereo BioPharma shareholders approve all resolutions at annual meeting By Investing.com - Investing.com Australia
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming DeadlinesMREO - Eastern Progress
Mereo BioPharma shareholders approve all resolutions at annual meeting - Investing.com
Mereo BioPharma (NASDAQ: MREO) gains investor approval for pay and share issuance powers - Stock Titan
Mereo BioPharma Reports Q1 2026 Financial Results and Updates on Setrusumab, Alvelestat, and Vantictumab Clinical Progress - Minichart
Mereo BioPharma (NASDAQ: MREO) Q1 2026 loss narrows as setrusumab data mixed - Stock Titan
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Investing News Network
Mereo BioPharma Reports Q1 2026 Financial Results, Advances Setrusumab and Alvelestat Clinical Programs, and Provides Cash Runway Update - Minichart
[10-Q] Mereo BioPharma Group plc Quarterly Earnings Report - Stock Titan
Mereo BioPharma (NASDAQ: MREO) halves Q1 loss and outlines key trial plans - Stock Titan
Trials miss fracture goals, but Mereo drug boosts bone density in OI - Stock Titan
MREO Stock Price, Quote & Chart | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) - ChartMill
Mereo BioPharma (MREO) 2026 AGM to vote on share issuance, pay and directors - Stock Titan
MREO FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - ChartMill
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm - Barchart.com
MREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit - Morningstar
MREO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Mereo BioPharma Investors of Securities Class Action Deadline on April 6, 2026 - Sahm
MREO Deadline: Rosen Law Firm Urges Mereo BioPharma Group plc (NASDAQ: MREO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - ChartMill
DEADLINE APPROACHING: Berger Montague Advises BioPharma Group PLC (NASDAQ: MREO) Investors to Inquire About a Securities Fraud Class Action by April 6, 2026 - ChartMill
Pomerantz LLP Shares Class Action Details With Shareholders in Mereo BioPharma Group plc – MREO - ACCESS Newswire
Pomerantz LLP Notifies Investors of Class Action Filing Against Mereo BioPharma Group plc – MREO - ACCESS Newswire
MREO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Mereo BioPharma Group plc Securities Lawsuit -- The Gross Law Firm - Barchart.com
Mereo BioPharma (MREO) director Jenkins to leave board at May 2026 AGM - Stock Titan
MREO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - Morningstar
Mereo Biopharma Group Plc Adr (MREO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.50%
0.57%
자본화:
|
볼륨(24시간):